CareersPipelineCollaboration RareInnovation SVGOMG The best SVG optimizer and minifier Open SVG Paste markup Demo Contribute SVGOMG provides you several options to clean and compress your SVG files. Clean up, remove, merge, minify. Upload or copy the source of your SVG to get started! 947 bytes → 267 bytes 28.19% Finance peopleAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes
Hansa Biopharma

Virtual Investor Event

Autoimmune Deep Dive
Guillain-Barré Syndrome 

Join Hansa Biopharma for an investor event featuring KOLs David R. Cornblath, MD (Johns Hopkins University), and Simon Rinaldi, MRCP(Neuro), PhD (University of Oxford), who will discuss the unmet need and current treatment landscape for Guillain-Barré syndrome (GBS),  an acute, rare, paralyzing inflammatory disease of the peripheral nervous system.

28 April 2025, 14:00 CEST / 8:00 AM ET

Register and attend

Hansa Medical’s Annual Report of 2013 has been published (In Swedish)

30 Apr 2014, 15:00
Regulatory information
The Hansa Medical Annual Report of 2013 (In Swedish) has been published at the corporate website www.hansamedical.com, and is attached to this press release.

A print version of the annual report can be ordered as follows:

  • E-mail, [email protected]
  • Letter, Hansa Medical AB, Investor Relations, P.O. Box 785, 220 07 Lund, Sweden
  • Fax, +46 46 12 77 75
  • Phone, +46 46 16 56 70

Files

For further information, please contact:
Hansa Medical AB
Emanuel Björne, CEO Hansa Medical AB (publ)
Mobile: 46 707 17 54 77
E-mail: [email protected]
www.hansamedical.com

Hansa Medical pursues clinical development and commercialization of innovative pharmaceuticals and diagnostic methods for the benefit of patients with serious and rare inflammatory diseases. The portfolio includes a marketed diagnostic product, a drug candidate in clinical development, and a preclinical research project. Major shareholders are Bo Håkansson via Farstorps Gård AB, and Nexttobe AB. Hansa Medical is listed on NASDAQ OMX First North (HMED) and Remium Nordic AB is the company’s Certified Adviser. The information in this press release is such information that Hansa Medical AB (publ) is obliged to disclose under the Securities Market Act and/or the Financial Instruments Trading Act. The information was made public on April 30, 2014 at 15:00 CET.